Make poster of emergency drugs labetolol ondanseteron metaclroprmide d

Make poster of emergency drugs labetolol ondanseteron metaclroprmide doubtine adrelaine non adrelaine pantop Tramadol tipetodol livecretcream phenytoin dopamine avil pcm dopamine nitroglycerin vancomycin furesimide heaparin vitamin k calcium carbonate half life mechanism and half life make chart poster
Checking Date & Time
Reading File
Finding Sources
Running Command
mkdir -p /home/daytona/workspace/emergency-drugs-poster && ls /home/daytona/workspace/
Writing File
~/emergency-drugs-poster/emergency_drugs_poster.html
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Emergency Drugs – Mechanism & Half-Life Reference Poster</title>
<style>
  @import url('https://fonts.googleapis.com/css2?family=Roboto:wght@300;400;500;700;900&family=Oswald:wght@600;700&display=swap');

  * { margin: 0; padding: 0; box-sizing: border-box; }

  body {
    background: #0a0a1a;
    font-family: 'Roboto', sans-serif;
    color: #e0e0e0;
    padding: 20px;
  }

  .poster {
    max-width: 1400px;
    margin: 0 auto;
    background: linear-gradient(135deg, #0d1b2a 0%, #1a0a2e 50%, #0d2a1b 100%);
    border: 3px solid #ff4444;
    border-radius: 16px;
    padding: 30px;
    box-shadow: 0 0 60px rgba(255, 68, 68, 0.4), 0 0 120px rgba(255, 68, 68, 0.1);
  }

  /* ── HEADER ── */
  .header {
    text-align: center;
    margin-bottom: 28px;
    position: relative;
    padding-bottom: 20px;
    border-bottom: 2px solid rgba(255,68,68,0.5);
  }
  .header::before {
    content: "🚨";
    font-size: 2.8rem;
    display: block;
    margin-bottom: 8px;
  }
  .header h1 {
    font-family: 'Oswald', sans-serif;
    font-size: 2.8rem;
    font-weight: 700;
    color: #ff4444;
    text-transform: uppercase;
    letter-spacing: 4px;
    text-shadow: 0 0 20px rgba(255,68,68,0.7);
  }
  .header h2 {
    font-size: 1.1rem;
    font-weight: 300;
    color: #aaa;
    letter-spacing: 3px;
    margin-top: 6px;
    text-transform: uppercase;
  }
  .header .badge {
    display: inline-block;
    margin-top: 10px;
    background: rgba(255,68,68,0.15);
    border: 1px solid #ff4444;
    border-radius: 20px;
    padding: 4px 20px;
    font-size: 0.78rem;
    color: #ff9999;
    letter-spacing: 2px;
  }

  /* ── CATEGORY LABELS ── */
  .category-row {
    display: flex;
    gap: 10px;
    margin-bottom: 18px;
    flex-wrap: wrap;
    justify-content: center;
  }
  .cat-badge {
    padding: 5px 14px;
    border-radius: 20px;
    font-size: 0.72rem;
    font-weight: 700;
    letter-spacing: 1px;
    text-transform: uppercase;
    border: 1px solid;
  }
  .cat-cv    { background: rgba(255,82,82,0.15);   border-color: #ff5252; color: #ff8a8a; }
  .cat-neuro { background: rgba(128,0,255,0.15);   border-color: #9c27b0; color: #ce93d8; }
  .cat-gi    { background: rgba(0,188,212,0.15);   border-color: #00bcd4; color: #80deea; }
  .cat-ant   { background: rgba(255,193,7,0.15);   border-color: #ffc107; color: #ffe082; }
  .cat-anal  { background: rgba(76,175,80,0.15);   border-color: #4caf50; color: #a5d6a7; }
  .cat-anti  { background: rgba(33,150,243,0.15);  border-color: #2196f3; color: #90caf9; }
  .cat-coag  { background: rgba(255,152,0,0.15);   border-color: #ff9800; color: #ffcc80; }
  .cat-elec  { background: rgba(233,30,99,0.15);   border-color: #e91e63; color: #f48fb1; }
  .cat-derm  { background: rgba(0,150,136,0.15);   border-color: #009688; color: #80cbc4; }
  .cat-diur  { background: rgba(63,81,181,0.15);   border-color: #3f51b5; color: #9fa8da; }

  /* ── TABLE ── */
  .table-wrapper {
    overflow-x: auto;
    border-radius: 10px;
    border: 1px solid rgba(255,255,255,0.1);
  }

  table {
    width: 100%;
    border-collapse: collapse;
    font-size: 0.82rem;
    min-width: 1000px;
  }

  thead th {
    background: linear-gradient(135deg, #1a0000, #2a0000);
    color: #ff4444;
    font-family: 'Oswald', sans-serif;
    font-size: 0.85rem;
    font-weight: 600;
    letter-spacing: 1.5px;
    text-transform: uppercase;
    padding: 14px 12px;
    border-bottom: 2px solid #ff4444;
    border-right: 1px solid rgba(255,255,255,0.08);
    text-align: left;
    white-space: nowrap;
  }
  thead th:last-child { border-right: none; }

  tbody tr {
    border-bottom: 1px solid rgba(255,255,255,0.06);
    transition: background 0.2s;
  }
  tbody tr:hover { background: rgba(255,255,255,0.04); }

  tbody td {
    padding: 11px 12px;
    border-right: 1px solid rgba(255,255,255,0.05);
    vertical-align: top;
    line-height: 1.45;
  }
  tbody td:last-child { border-right: none; }

  /* Drug name column */
  .drug-name {
    font-weight: 700;
    font-size: 0.88rem;
    color: #fff;
    white-space: nowrap;
  }
  .drug-generic {
    font-size: 0.72rem;
    color: #888;
    font-style: italic;
    margin-top: 2px;
  }
  .drug-brand {
    font-size: 0.7rem;
    color: #aaa;
  }

  /* Category pill */
  .cat-pill {
    display: inline-block;
    padding: 2px 8px;
    border-radius: 10px;
    font-size: 0.68rem;
    font-weight: 600;
    border: 1px solid;
    white-space: nowrap;
  }

  /* Half-life */
  .hl {
    font-weight: 700;
    font-size: 0.92rem;
    color: #ffd54f;
    white-space: nowrap;
  }
  .hl-note {
    font-size: 0.68rem;
    color: #aaa;
    margin-top: 2px;
  }

  /* Mechanism */
  .moa { color: #b3e5fc; }
  .moa strong { color: #4fc3f7; }

  /* Dose / Route */
  .dose { color: #c8e6c9; font-size: 0.78rem; }
  .route {
    display: inline-block;
    background: rgba(255,255,255,0.08);
    border-radius: 4px;
    padding: 1px 5px;
    font-size: 0.65rem;
    margin-right: 3px;
    margin-top: 2px;
    color: #ccc;
  }

  /* Indication */
  .ind { color: #e8d5f5; font-size: 0.78rem; }

  /* Caution */
  .caut { color: #ff8a80; font-size: 0.72rem; }
  .caut::before { content: "⚠ "; }

  /* Row colour accent per category */
  tr.row-cv    { border-left: 3px solid #ff5252; }
  tr.row-neuro { border-left: 3px solid #9c27b0; }
  tr.row-gi    { border-left: 3px solid #00bcd4; }
  tr.row-ant   { border-left: 3px solid #ffc107; }
  tr.row-anal  { border-left: 3px solid #4caf50; }
  tr.row-anti  { border-left: 3px solid #2196f3; }
  tr.row-coag  { border-left: 3px solid #ff9800; }
  tr.row-elec  { border-left: 3px solid #e91e63; }
  tr.row-derm  { border-left: 3px solid #009688; }
  tr.row-diur  { border-left: 3px solid #3f51b5; }

  /* ── FOOTER ── */
  .footer {
    margin-top: 24px;
    border-top: 1px solid rgba(255,255,255,0.1);
    padding-top: 16px;
    display: flex;
    justify-content: space-between;
    align-items: center;
    flex-wrap: wrap;
    gap: 10px;
  }
  .footer-note {
    font-size: 0.72rem;
    color: #666;
    max-width: 700px;
  }
  .footer-note strong { color: #ff8a80; }
  .footer-date {
    font-size: 0.72rem;
    color: #555;
    text-align: right;
  }

  /* Column widths */
  col.c1 { width: 130px; }
  col.c2 { width: 80px;  }
  col.c3 { width: 100px; }
  col.c4 { width: 260px; }
  col.c5 { width: 130px; }
  col.c6 { width: 150px; }
  col.c7 { width: 160px; }
</style>
</head>
<body>
<div class="poster">

  <!-- HEADER -->
  <div class="header">
    <h1>Emergency Drugs Reference</h1>
    <h2>Mechanism of Action &amp; Half-Life Chart</h2>
    <div class="badge">ICU · ER · WARD · CRITICAL CARE</div>
  </div>

  <!-- CATEGORY LEGEND -->
  <div class="category-row">
    <span class="cat-badge cat-cv">❤ Cardiovascular</span>
    <span class="cat-badge cat-neuro">🧠 Neuro / Anticonvulsant</span>
    <span class="cat-badge cat-gi">💊 GI / Antiemetic</span>
    <span class="cat-badge cat-anal">💉 Analgesic / Opioid</span>
    <span class="cat-badge cat-anti">🔵 Antibiotic</span>
    <span class="cat-badge cat-coag">🟠 Anticoagulant / Reversal</span>
    <span class="cat-badge cat-elec">🩸 Electrolyte</span>
    <span class="cat-badge cat-diur">🟣 Diuretic</span>
    <span class="cat-badge cat-ant">🟡 Antacid / GI Protective</span>
    <span class="cat-badge cat-derm">🟢 Dermatology / Topical</span>
  </div>

  <!-- MAIN TABLE -->
  <div class="table-wrapper">
  <table>
    <colgroup>
      <col class="c1"><col class="c2"><col class="c3"><col class="c4"><col class="c5"><col class="c6"><col class="c7">
    </colgroup>
    <thead>
      <tr>
        <th>#&nbsp; Drug Name</th>
        <th>Category</th>
        <th>Half-Life</th>
        <th>Mechanism of Action</th>
        <th>Route / Dose</th>
        <th>Key Indication</th>
        <th>Key Caution</th>
      </tr>
    </thead>
    <tbody>

      <!-- 1 LABETALOL -->
      <tr class="row-cv">
        <td>
          <div class="drug-name">1. Labetalol</div>
          <div class="drug-generic">labetalol HCl</div>
        </td>
        <td><span class="cat-pill cat-cv">CV</span></td>
        <td>
          <div class="hl">3 – 8 h</div>
          <div class="hl-note">Onset IV: 2–5 min</div>
        </td>
        <td class="moa">
          <strong>α₁ + β₁ + β₂ non-selective adrenergic antagonist</strong> (α:β ratio ~1:7 IV, 1:3 oral). Reduces BP by ↓ SVR without reflex tachycardia. Also has mild ISA on β₂.
        </td>
        <td class="dose">
          <span class="route">IV</span>10–80 mg bolus;<br>
          <span class="route">Infusion</span>1–2 mg/min<br>
          <span class="route">PO</span>100–400 mg BD
        </td>
        <td class="ind">Hypertensive emergency, pre-eclampsia, aortic dissection</td>
        <td class="caut">Avoid in asthma, bradycardia, AV block, decompensated HF</td>
      </tr>

      <!-- 2 ONDANSETRON -->
      <tr class="row-gi">
        <td>
          <div class="drug-name">2. Ondansetron</div>
          <div class="drug-generic">(Zofran)</div>
        </td>
        <td><span class="cat-pill cat-gi">GI</span></td>
        <td>
          <div class="hl">3 – 5 h</div>
          <div class="hl-note">Onset IV: 30 min</div>
        </td>
        <td class="moa">
          <strong>Selective 5-HT₃ receptor antagonist.</strong> Blocks serotonin receptors in the gut vagal afferents and chemoreceptor trigger zone (CTZ), suppressing emetic reflex.
        </td>
        <td class="dose">
          <span class="route">IV/IM</span>4–8 mg<br>
          <span class="route">PO</span>4–8 mg TDS
        </td>
        <td class="ind">Post-op / chemotherapy / radiation-induced nausea &amp; vomiting</td>
        <td class="caut">QT prolongation; avoid concurrent QT-prolonging drugs; serotonin syndrome risk</td>
      </tr>

      <!-- 3 METOCLOPRAMIDE -->
      <tr class="row-gi">
        <td>
          <div class="drug-name">3. Metoclopramide</div>
          <div class="drug-generic">(Reglan / Perinorm)</div>
        </td>
        <td><span class="cat-pill cat-gi">GI</span></td>
        <td>
          <div class="hl">4 – 6 h</div>
          <div class="hl-note">Onset IV: 1–3 min</div>
        </td>
        <td class="moa">
          <strong>Dopamine D₂ antagonist + weak 5-HT₃ antagonist + 5-HT₄ agonist.</strong> ↑ GI motility; blocks dopamine in CTZ → antiemetic. Also stimulates acetylcholine release.
        </td>
        <td class="dose">
          <span class="route">IV/IM</span>10 mg 8-hourly<br>
          <span class="route">PO</span>10 mg before meals
        </td>
        <td class="ind">Nausea, gastroparesis, GERD, gastric emptying</td>
        <td class="caut">Extrapyramidal side effects (EPS), tardive dyskinesia; avoid in Parkinson's; reduce dose in renal impairment</td>
      </tr>

      <!-- 4 DOBUTAMINE -->
      <tr class="row-cv">
        <td>
          <div class="drug-name">4. Dobutamine</div>
          <div class="drug-generic">(Dobutrex)</div>
        </td>
        <td><span class="cat-pill cat-cv">CV</span></td>
        <td>
          <div class="hl">2 min</div>
          <div class="hl-note">Very short; infusion only</div>
        </td>
        <td class="moa">
          <strong>Synthetic β₁-adrenergic agonist</strong> (predominant), mild β₂ + α₁ activity. ↑ cardiac contractility (inotropy) and HR; minimal effect on SVR. ↑ CO without marked ↑ BP.
        </td>
        <td class="dose">
          <span class="route">IV infusion</span>2–20 µg/kg/min<br>titrated to effect
        </td>
        <td class="ind">Acute decompensated HF, cardiogenic shock, low-output states</td>
        <td class="caut">Can precipitate arrhythmias; tachycardia; caution in AF; tolerance develops within 48–72 h</td>
      </tr>

      <!-- 5 ADRENALINE (Epinephrine) -->
      <tr class="row-cv">
        <td>
          <div class="drug-name">5. Adrenaline</div>
          <div class="drug-generic">Epinephrine</div>
        </td>
        <td><span class="cat-pill cat-cv">CV</span></td>
        <td>
          <div class="hl">&lt; 5 min</div>
          <div class="hl-note">Plasma t½ ~2 min</div>
        </td>
        <td class="moa">
          <strong>Non-selective α₁, α₂, β₁, β₂ adrenergic agonist (endogenous catecholamine).</strong><br>
          Low dose: β-dominant → ↑HR, bronchodilation.<br>
          High dose: α-dominant → ↑ SVR, vasoconstriction.<br>
          ↑ cAMP via adenylyl cyclase.
        </td>
        <td class="dose">
          <span class="route">IV</span>1 mg (1:10,000) per 3–5 min CPR<br>
          <span class="route">IM</span>0.3–0.5 mg (1:1,000) anaphylaxis<br>
          <span class="route">Infusion</span>0.01–1 µg/kg/min
        </td>
        <td class="ind">Cardiac arrest (VF/PEA/asystole), anaphylaxis, severe bronchospasm</td>
        <td class="caut">Hypertensive crisis, arrhythmias; avoid in cocaine toxicity; extreme tissue necrosis if extravasated</td>
      </tr>

      <!-- 6 NORADRENALINE (Norepinephrine) -->
      <tr class="row-cv">
        <td>
          <div class="drug-name">6. Noradrenaline</div>
          <div class="drug-generic">Norepinephrine (Levophed)</div>
        </td>
        <td><span class="cat-pill cat-cv">CV</span></td>
        <td>
          <div class="hl">1 – 2 min</div>
          <div class="hl-note">Rapid MAO/COMT metabolism</div>
        </td>
        <td class="moa">
          <strong>Potent α₁ + α₂ agonist; mild β₁ agonist; negligible β₂.</strong> Causes intense vasoconstriction → ↑ SVR → ↑ MAP. Reflex bradycardia may occur. Minimal direct chronotropy.
        </td>
        <td class="dose">
          <span class="route">IV infusion</span>0.01–3 µg/kg/min via central line
        </td>
        <td class="ind">Distributive / septic shock (first-line vasopressor), neurogenic shock</td>
        <td class="caut">Tissue necrosis if extravasated; ↓ renal/splanchnic blood flow; hypertension; peripheral ischaemia</td>
      </tr>

      <!-- 7 PANTOPRAZOLE -->
      <tr class="row-ant">
        <td>
          <div class="drug-name">7. Pantoprazole</div>
          <div class="drug-generic">(Pantop / Protonix)</div>
        </td>
        <td><span class="cat-pill cat-ant">PPI</span></td>
        <td>
          <div class="hl">1 – 2 h</div>
          <div class="hl-note">Effect lasts 24 h (irreversible)</div>
        </td>
        <td class="moa">
          <strong>Proton-pump inhibitor (PPI).</strong> Prodrug activated in acidic canaliculi → irreversibly inhibits H⁺/K⁺-ATPase (proton pump) on parietal cell luminal membrane → suppresses gastric acid secretion.
        </td>
        <td class="dose">
          <span class="route">IV</span>40 mg OD/BD<br>
          <span class="route">PO</span>20–40 mg OD
        </td>
        <td class="ind">GERD, peptic ulcer, stress ulcer prophylaxis, Zollinger-Ellison syndrome, upper GI bleed</td>
        <td class="caut">Hypomagnesaemia (long-term); C. difficile risk; ↓ clopidogrel efficacy; B₁₂ deficiency (long-term)</td>
      </tr>

      <!-- 8 TRAMADOL -->
      <tr class="row-anal">
        <td>
          <div class="drug-name">8. Tramadol</div>
          <div class="drug-generic">(Ultram, Tramazac)</div>
        </td>
        <td><span class="cat-pill cat-anal">Analgesic</span></td>
        <td>
          <div class="hl">6 – 7 h</div>
          <div class="hl-note">Active metabolite M1: ~9 h</div>
        </td>
        <td class="moa">
          <strong>Dual mechanism:</strong> (1) Weak μ-opioid receptor agonist (10× weaker than morphine). (2) Inhibits reuptake of serotonin &amp; norepinephrine in descending pain pathways. Modulates pain perception centrally.
        </td>
        <td class="dose">
          <span class="route">IV/IM</span>50–100 mg 6-hourly<br>
          <span class="route">PO</span>50–100 mg 4–6 hourly<br>Max 400 mg/day
        </td>
        <td class="ind">Moderate-to-severe pain, post-operative pain, neuropathic pain</td>
        <td class="caut">Serotonin syndrome (with SSRIs); lowers seizure threshold; avoid in renal failure; dependence potential</td>
      </tr>

      <!-- 9 TAPENTADOL -->
      <tr class="row-anal">
        <td>
          <div class="drug-name">9. Tapentadol</div>
          <div class="drug-generic">(Nucynta / Tapal)</div>
        </td>
        <td><span class="cat-pill cat-anal">Analgesic</span></td>
        <td>
          <div class="hl">4 – 5 h</div>
          <div class="hl-note">Immediate release form</div>
        </td>
        <td class="moa">
          <strong>Dual mechanism (MOR-NRI):</strong> (1) μ-opioid receptor (MOR) agonist. (2) Norepinephrine reuptake inhibitor (NRI). Combines opioid + non-opioid pain modulation in a single molecule; less serotonergic activity vs tramadol.
        </td>
        <td class="dose">
          <span class="route">PO</span>50–100 mg 4–6 hourly<br>
          Max 500 mg/day (naive)<br>
          Max 600 mg/day (tolerant)
        </td>
        <td class="ind">Moderate-to-severe acute pain, diabetic peripheral neuropathy</td>
        <td class="caut">MAOIs (contraindicated); serotonin syndrome; seizure risk; dependence; avoid in severe hepatic/renal impairment</td>
      </tr>

      <!-- 10 LIVOCETRIZINE CREAM (Levocetirizine) -->
      <tr class="row-derm">
        <td>
          <div class="drug-name">10. Levocetirizine</div>
          <div class="drug-generic">(Livocet / Xyzal)</div>
        </td>
        <td><span class="cat-pill cat-derm">Antihistamine</span></td>
        <td>
          <div class="hl">6 – 10 h</div>
          <div class="hl-note">Plasma; renal excretion</div>
        </td>
        <td class="moa">
          <strong>Selective H₁-receptor inverse agonist</strong> (R-enantiomer of cetirizine). Stabilises H₁ receptor in inactive conformation, ↓ histamine-mediated inflammation, pruritus, bronchoconstriction, and vasodilation. Minimal CNS penetration (non-sedating).
        </td>
        <td class="dose">
          <span class="route">PO</span>5 mg OD (evening)<br>
          <span class="route">Syrup</span>2.5 mg OD (&lt;6 yr)<br>
          <span class="route">Topical cream</span>0.1% – as per indication
        </td>
        <td class="ind">Allergic rhinitis, chronic urticaria, atopic dermatitis, pruritus</td>
        <td class="caut">Reduce dose in renal impairment (CrCl &lt;50); somnolence at high dose; avoid alcohol</td>
      </tr>

      <!-- 11 PHENYTOIN -->
      <tr class="row-neuro">
        <td>
          <div class="drug-name">11. Phenytoin</div>
          <div class="drug-generic">(Dilantin / Eptoin)</div>
        </td>
        <td><span class="cat-pill cat-neuro">Anticonvulsant</span></td>
        <td>
          <div class="hl">20 – 60 h</div>
          <div class="hl-note">Non-linear (Michaelis-Menten) kinetics; therapeutic range 10–20 µg/mL</div>
        </td>
        <td class="moa">
          <strong>Voltage-gated sodium channel blocker.</strong> Binds to inactivated Na⁺ channels → prolongs inactivated state → ↓ neuronal repetitive firing. Also ↓ calcium flux across neuronal membranes.
        </td>
        <td class="dose">
          <span class="route">IV (load)</span>15–20 mg/kg at ≤50 mg/min<br>
          <span class="route">Maintenance</span>5–7 mg/kg/day<br>
          <span class="route">PO</span>100 mg TDS
        </td>
        <td class="ind">Status epilepticus (2nd line), tonic-clonic &amp; partial seizures, post-neurosurgery prophylaxis</td>
        <td class="caut">Hypotension &amp; arrhythmia with rapid IV; purple glove syndrome; zero-order kinetics (toxic levels with small dose changes); teratogenic (fetal hydantoin syndrome); numerous CYP450 interactions</td>
      </tr>

      <!-- 12 DOPAMINE -->
      <tr class="row-cv">
        <td>
          <div class="drug-name">12. Dopamine</div>
          <div class="drug-generic">(Intropin, Revimine)</div>
        </td>
        <td><span class="cat-pill cat-cv">Vasopressor</span></td>
        <td>
          <div class="hl">1 – 2 min</div>
          <div class="hl-note">Rapid MAO/COMT metabolism</div>
        </td>
        <td class="moa">
          <strong>Dose-dependent receptor activation:</strong><br>
          <strong>Low (1–5 µg/kg/min):</strong> D₁/D₂ → renal &amp; mesenteric vasodilation.<br>
          <strong>Medium (5–10 µg/kg/min):</strong> β₁ → ↑ inotropy &amp; HR.<br>
          <strong>High (&gt;10 µg/kg/min):</strong> α₁ → vasoconstriction, ↑ SVR.
        </td>
        <td class="dose">
          <span class="route">IV infusion</span>1–20 µg/kg/min via central line
        </td>
        <td class="ind">Hemodynamic instability, cardiogenic shock, septic shock (2nd line), bradycardia with hypotension</td>
        <td class="caut">Arrhythmias; tachycardia; tissue necrosis if extravasated; ↑ mortality in some shock states vs noradrenaline; ↓ prolactin (D₂)</td>
      </tr>

      <!-- 13 AVIL (Pheniramine) -->
      <tr class="row-derm">
        <td>
          <div class="drug-name">13. Avil</div>
          <div class="drug-generic">Pheniramine maleate</div>
        </td>
        <td><span class="cat-pill cat-derm">Antihistamine</span></td>
        <td>
          <div class="hl">16 – 19 h</div>
          <div class="hl-note">1st-generation; renal excretion</div>
        </td>
        <td class="moa">
          <strong>Competitive H₁ receptor antagonist</strong> (1st generation, alkylamine class). Crosses BBB → sedation, antipruritic, antiemetic effects. Also mild anticholinergic &amp; weak local anaesthetic properties.
        </td>
        <td class="dose">
          <span class="route">IM/IV</span>22.75–45.5 mg (1–2 mL)<br>
          <span class="route">PO</span>25 mg TDS–QDS
        </td>
        <td class="ind">Allergic reactions, anaphylaxis (adjunct), urticaria, drug reactions, pruritus, blood transfusion reactions</td>
        <td class="caut">Sedation; anticholinergic effects (urinary retention, dry mouth, glaucoma); do not use alone in anaphylaxis</td>
      </tr>

      <!-- 14 PARACETAMOL (PCM) -->
      <tr class="row-anal">
        <td>
          <div class="drug-name">14. Paracetamol</div>
          <div class="drug-generic">Acetaminophen (PCM / Crocin)</div>
        </td>
        <td><span class="cat-pill cat-anal">Analgesic/Antipyretic</span></td>
        <td>
          <div class="hl">1.5 – 3 h</div>
          <div class="hl-note">Overdose prolongs t½ (hepatotoxicity)</div>
        </td>
        <td class="moa">
          <strong>Central COX-3 inhibition + endocannabinoid reuptake inhibition.</strong> Inhibits prostaglandin synthesis centrally (hypothalamus) → antipyresis &amp; analgesia. Minimal peripheral anti-inflammatory effect. Exact mechanism debated.
        </td>
        <td class="dose">
          <span class="route">IV</span>1 g over 15 min 4–6 hourly (max 4 g/day)<br>
          <span class="route">PO</span>500 mg–1 g QDS
        </td>
        <td class="ind">Mild-moderate pain, fever, post-operative analgesia, safe in pregnancy</td>
        <td class="caut">Hepatotoxicity in overdose (via NAPQI); reduce dose in hepatic disease, malnutrition, alcohol use; antidote: N-acetylcysteine (NAC)</td>
      </tr>

      <!-- 15 NITROGLYCERIN -->
      <tr class="row-cv">
        <td>
          <div class="drug-name">15. Nitroglycerin</div>
          <div class="drug-generic">GTN / Glyceryl trinitrate</div>
        </td>
        <td><span class="cat-pill cat-cv">Vasodilator</span></td>
        <td>
          <div class="hl">1 – 4 min</div>
          <div class="hl-note">Rapid hepatic metabolism</div>
        </td>
        <td class="moa">
          <strong>Nitrovasodilator → releases Nitric Oxide (NO).</strong> NO activates soluble guanylyl cyclase → ↑ cGMP → smooth muscle relaxation. Predominantly venodilation (↓ preload); coronary &amp; arterial vasodilation at higher doses (↓ afterload).
        </td>
        <td class="dose">
          <span class="route">SL</span>0.4 mg q5 min × 3<br>
          <span class="route">IV</span>5–200 µg/min infusion<br>
          <span class="route">Patch</span>0.2–0.8 mg/h (12 h on/off)
        </td>
        <td class="ind">Acute angina, ACS, hypertensive emergency, acute pulmonary oedema, acute LV failure</td>
        <td class="caut">Hypotension; headache; tolerance (nitrate-free interval required); contraindicated with PDE-5 inhibitors (sildenafil); do not use in RV infarct (preload dependent)</td>
      </tr>

      <!-- 16 VANCOMYCIN -->
      <tr class="row-anti">
        <td>
          <div class="drug-name">16. Vancomycin</div>
          <div class="drug-generic">(Vancocin)</div>
        </td>
        <td><span class="cat-pill cat-anti">Antibiotic</span></td>
        <td>
          <div class="hl">4 – 11 h</div>
          <div class="hl-note">Normal renal function; prolonged in renal failure; TDM required</div>
        </td>
        <td class="moa">
          <strong>Glycopeptide antibiotic.</strong> Binds to D-Ala–D-Ala terminus of peptidoglycan precursors → prevents transglycosylation &amp; transpeptidation → inhibits bacterial cell wall synthesis. Bactericidal against Gram-positive organisms.
        </td>
        <td class="dose">
          <span class="route">IV</span>15–20 mg/kg 8–12 hourly<br>
          Infuse over ≥60 min<br>Target trough: 15–20 µg/mL (or AUC/MIC 400–600)
        </td>
        <td class="ind">MRSA infections, serious Gram-positive infections, C. difficile colitis (oral), endocarditis</td>
        <td class="caut">Red man syndrome (slow infusion ↓ risk); nephrotoxicity; ototoxicity; dose adjust in renal impairment; TDM monitoring essential</td>
      </tr>

      <!-- 17 FUROSEMIDE -->
      <tr class="row-diur">
        <td>
          <div class="drug-name">17. Furosemide</div>
          <div class="drug-generic">Frusemide (Lasix)</div>
        </td>
        <td><span class="cat-pill cat-diur">Loop Diuretic</span></td>
        <td>
          <div class="hl">0.5 – 2 h</div>
          <div class="hl-note">Onset IV: 2–5 min; PO: 30–60 min; prolonged in renal/hepatic failure</div>
        </td>
        <td class="moa">
          <strong>Inhibits Na⁺-K⁺-2Cl⁻ (NKCC2) co-transporter</strong> in the thick ascending limb of Loop of Henle. ↓ reabsorption of Na⁺, K⁺, Cl⁻ → ↑ urine output. Also venodilates acutely (↓ preload before diuresis begins).
        </td>
        <td class="dose">
          <span class="route">IV</span>20–80 mg OD/BD (titrate)<br>
          <span class="route">PO</span>20–120 mg OD/BD<br>
          High-dose infusion: 5–40 mg/h
        </td>
        <td class="ind">Acute pulmonary oedema, heart failure, hypertension, hypercalcaemia, hyperkalaemia, oliguric renal failure</td>
        <td class="caut">Hypokalaemia; hyponatraemia; hypovolaemia; hypocalcaemia; ototoxicity (rapid high-dose IV); gout; monitor electrolytes</td>
      </tr>

      <!-- 18 HEPARIN -->
      <tr class="row-coag">
        <td>
          <div class="drug-name">18. Heparin</div>
          <div class="drug-generic">Unfractionated Heparin (UFH)</div>
        </td>
        <td><span class="cat-pill cat-coag">Anticoagulant</span></td>
        <td>
          <div class="hl">1 – 2 h</div>
          <div class="hl-note">Dose-dependent; prolonged in PE/massive thrombus; monitor aPTT</div>
        </td>
        <td class="moa">
          <strong>Activates antithrombin III (AT-III)</strong> by conformational change → AT-III irreversibly inhibits thrombin (IIa), Xa, IXa, XIa, XIIa. ↓ clot formation. Does NOT lyse existing clots. Reversed by protamine sulphate.
        </td>
        <td class="dose">
          <span class="route">IV bolus</span>80 units/kg<br>
          <span class="route">Infusion</span>18 units/kg/h (titrate to aPTT 60–100 s)<br>
          <span class="route">SC prophylaxis</span>5,000 units BD/TDS
        </td>
        <td class="ind">DVT/PE treatment &amp; prophylaxis, ACS, atrial fibrillation, CPB, haemodialysis</td>
        <td class="caut">HIT (heparin-induced thrombocytopaenia) – check platelets; bleeding risk; osteoporosis (long-term); antidote: protamine (1 mg per 100 units heparin)</td>
      </tr>

      <!-- 19 VITAMIN K -->
      <tr class="row-coag">
        <td>
          <div class="drug-name">19. Vitamin K</div>
          <div class="drug-generic">Phytomenadione (Konakion)</div>
        </td>
        <td><span class="cat-pill cat-coag">Coag Reversal</span></td>
        <td>
          <div class="hl">17 h</div>
          <div class="hl-note">Warfarin reversal: 6–12 h for INR effect</div>
        </td>
        <td class="moa">
          <strong>Cofactor for γ-carboxylation of Gla-proteins.</strong> Activated by vitamin K epoxide reductase → carboxylates clotting factors II, VII, IX, X (and proteins C &amp; S). Reverses warfarin/coumarin anticoagulation. Essential for haemostasis.
        </td>
        <td class="dose">
          <span class="route">IV (slow)</span>2–10 mg over 30 min<br>
          <span class="route">IM/SC</span>10 mg<br>
          <span class="route">Neonates</span>1 mg IM at birth (HDN prophylaxis)
        </td>
        <td class="ind">Warfarin reversal, haemorrhagic disease of newborn (HDN), liver disease coagulopathy, vitamin K deficiency</td>
        <td class="caut">Anaphylaxis with rapid IV (give slowly); will not correct factor replacement in emergencies (FFP faster); takes hours for full effect</td>
      </tr>

      <!-- 20 CALCIUM CARBONATE -->
      <tr class="row-elec">
        <td>
          <div class="drug-name">20. Calcium Carbonate</div>
          <div class="drug-generic">(Caltrate, Shelcal)</div>
        </td>
        <td><span class="cat-pill cat-elec">Electrolyte</span></td>
        <td>
          <div class="hl">Variable</div>
          <div class="hl-note">Calcium t½: ~1 h IV; depot effect PO; skeletal storage</div>
        </td>
        <td class="moa">
          <strong>Calcium supplementation + phosphate binder (in CKD).</strong> Replenishes Ca²⁺ for membrane stabilisation, myocardial contractility, neuromuscular function, coagulation (factor IV). In CKD: binds dietary phosphate in gut → ↓ hyperphosphataemia. IV calcium gluconate stabilises cardiac membranes in hyperkalaemia.
        </td>
        <td class="dose">
          <span class="route">PO</span>500 mg–1.5 g TDS with meals<br>
          <span class="route">Calcium gluconate IV</span>10 mL of 10% slow IV (cardiac stabilisation in hyperkalaemia)<br>
          <span class="route">Calcium chloride IV</span>5–10 mL of 10%
        </td>
        <td class="ind">Hypocalcaemia, osteoporosis, CKD-mineral bone disorder (MBD), hyperkalaemia (cardiac membrane stabilisation), antacid</td>
        <td class="caut">Hypercalcaemia; constipation; interactions with iron, tetracyclines; digoxin toxicity ↑ with Ca²⁺; nephrolithiasis with excess</td>
      </tr>

    </tbody>
  </table>
  </div>

  <!-- QUICK HALF-LIFE SUMMARY BAR -->
  <div style="margin-top: 22px;">
    <div style="font-family: 'Oswald', sans-serif; font-size: 0.9rem; color: #ff4444; letter-spacing: 2px; text-transform: uppercase; margin-bottom: 10px;">⏱ Quick Half-Life Reference</div>
    <div style="display: flex; flex-wrap: wrap; gap: 8px;">
      <!-- Ultra-short -->
      <div style="background: rgba(255,82,82,0.12); border: 1px solid rgba(255,82,82,0.3); border-radius: 8px; padding: 8px 14px; min-width: 160px;">
        <div style="font-size: 0.65rem; color: #ff8a8a; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 5px;">Ultra-Short (&lt; 5 min)</div>
        <div style="font-size: 0.75rem; color: #eee; line-height: 1.7;">
          Adrenaline — <b>&lt;2 min</b><br>
          Noradrenaline — <b>1–2 min</b><br>
          Dopamine — <b>1–2 min</b><br>
          Dobutamine — <b>~2 min</b><br>
          Nitroglycerin — <b>1–4 min</b>
        </div>
      </div>
      <!-- Short -->
      <div style="background: rgba(255,193,7,0.1); border: 1px solid rgba(255,193,7,0.3); border-radius: 8px; padding: 8px 14px; min-width: 160px;">
        <div style="font-size: 0.65rem; color: #ffe082; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 5px;">Short (30 min – 3 h)</div>
        <div style="font-size: 0.75rem; color: #eee; line-height: 1.7;">
          Furosemide — <b>0.5–2 h</b><br>
          Paracetamol — <b>1.5–3 h</b><br>
          Nitroglycerin — <b>1–4 min</b><br>
          Pantoprazole — <b>1–2 h</b><br>
          Heparin — <b>1–2 h</b>
        </div>
      </div>
      <!-- Moderate -->
      <div style="background: rgba(76,175,80,0.1); border: 1px solid rgba(76,175,80,0.3); border-radius: 8px; padding: 8px 14px; min-width: 160px;">
        <div style="font-size: 0.65rem; color: #a5d6a7; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 5px;">Moderate (3 – 10 h)</div>
        <div style="font-size: 0.75rem; color: #eee; line-height: 1.7;">
          Labetalol — <b>3–8 h</b><br>
          Ondansetron — <b>3–5 h</b><br>
          Metoclopramide — <b>4–6 h</b><br>
          Tramadol — <b>6–7 h</b><br>
          Tapentadol — <b>4–5 h</b><br>
          Levocetirizine — <b>6–10 h</b><br>
          Vancomycin — <b>4–11 h</b>
        </div>
      </div>
      <!-- Long -->
      <div style="background: rgba(33,150,243,0.1); border: 1px solid rgba(33,150,243,0.3); border-radius: 8px; padding: 8px 14px; min-width: 160px;">
        <div style="font-size: 0.65rem; color: #90caf9; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 5px;">Long (&gt;10 h)</div>
        <div style="font-size: 0.75rem; color: #eee; line-height: 1.7;">
          Avil (Pheniramine) — <b>16–19 h</b><br>
          Vitamin K — <b>~17 h</b><br>
          Phenytoin — <b>20–60 h</b><br>
          Calcium Carbonate — <b>variable</b>
        </div>
      </div>
    </div>
  </div>

  <!-- FOOTER -->
  <div class="footer">
    <div class="footer-note">
      <strong>⚠ Clinical Disclaimer:</strong> This chart is a quick-reference educational tool only. Always verify doses, contraindications, and drug interactions with current formularies, institutional protocols, and clinical judgment. Half-lives may vary with renal/hepatic impairment, age, drug interactions, and pathological states.
    </div>
    <div class="footer-date">
      Generated: April 2026<br>
      Sources: Katzung Pharmacology 16e · Washington Manual · Miller's Anesthesia 10e · Lippincott Pharmacology
    </div>
  </div>

</div>
</body>
</html>
Running Command
which wkhtmltopdf chromium-browser google-chrome 2>/dev/null; python3 -c "import weasyprint; print('weasyprint ok')" 2>/dev/null || echo "checking other options"
Running Command
python3 -c "from weasyprint import HTML; print('weasyprint available')" 2>&1; python3 -c "import pdfkit; print('pdfkit available')" 2>&1
Running Command
which libreoffice soffice pandoc 2>/dev/null; python3 -c "from reportlab.lib.pagesizes import A1; print('reportlab ok')" 2>&1
Running Command
cd /home/daytona/workspace/emergency-drugs-poster && libreoffice --headless --convert-to pdf emergency_drugs_poster.html --outdir . 2>&1
Running Command
cp /home/daytona/workspace/emergency-drugs-poster/emergency_drugs_poster.html /tmp/ep.html && libreoffice --headless --convert-to pdf /tmp/ep.html --outdir /tmp/ 2>&1 && cp /tmp/ep.pdf /home/daytona/workspace/emergency-drugs-poster/emergency_drugs_poster.pdf && echo "PDF created" && ls -lh /home/daytona/workspace/emergency-drugs-poster/
Your emergency drugs poster is ready! Here are your download links:
📥 Download Files

Format	Link
HTML (interactive, best rendering)	emergency drugs poster HTML File · HTML
PDF (print-ready)	emergency drugs poster PDF Document · PDF
What's included in the poster

The poster is a dark-themed, color-coded reference chart covering all 20 drugs you listed (with corrected spellings):
#	Drug	Category
1	Labetalol	Cardiovascular (α+β blocker)
2	Ondansetron	GI / Antiemetic
3	Metoclopramide	GI / Antiemetic
4	Dobutamine	Cardiovascular (inotrope)
5	Adrenaline (Epinephrine)	Cardiovascular / Emergency
6	Noradrenaline (Norepinephrine)	Cardiovascular / Vasopressor
7	Pantoprazole	PPI / GI Protective
8	Tramadol	Analgesic
9	Tapentadol	Analgesic
10	Levocetirizine (Livocet cream)	Antihistamine / Dermatology
11	Phenytoin	Anticonvulsant
12	Dopamine	Vasopressor / Inotrope
13	Avil (Pheniramine)	Antihistamine
14	Paracetamol (PCM)	Analgesic / Antipyretic
15	Nitroglycerin (GTN)	Vasodilator
16	Vancomycin	Antibiotic
17	Furosemide	Loop Diuretic
18	Heparin	Anticoagulant
19	Vitamin K	Coagulation Reversal
20	Calcium Carbonate	Electrolyte
Each drug entry contains:

Mechanism of Action (detailed, receptor-level)
Half-Life (with onset notes)
Route & Emergency Dose
Key Indications
Key Cautions / Contraindications
Plus a color-coded Quick Half-Life Summary bar grouping drugs into Ultra-Short / Short / Moderate / Long categories.
Note: Drug names were interpreted and corrected from your list (e.g. doubtine → Dobutamine, adrelaine → Adrenaline, non adrelaine → Noradrenaline, tipetodol → Tapentadol, livecretcream → Levocetirizine, furesimide → Furosemide, heaparin → Heparin). Let me know if any drug needs to be changed.
This is a shared conversation. Sign in to Orris to start your own chat.